How to Approach Your Doctor to Prescribe LDN

Apr 28, 2022

14 min read

Updated: Aug 7

How to Approach Your Doctor About Low-Dose Naltrexone (LDN): A Patient's Guide to a Productive Conversation

Written and medically reviewed by: Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com

Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Low-dose naltrexone (LDN) is used off-label for the conditions discussed below; it is not FDA-approved for any of them. All therapeutic decisions, including the use of LDN, should be made in consultation with a qualified healthcare provider who can evaluate individual circumstances. Nothing in this article creates a physician-patient relationship.

Last updated: August 2026

The Short Answer

If you believe low-dose naltrexone might help your condition, come prepared: bring published evidence, frame your request as a question rather than a demand, and understand why your physician may hesitate. This article gives you the tools to have that conversation — honestly, respectfully, and with the best available evidence in hand.

Introduction

One of the most common frustrations I hear from patients — in my own practice and through the LDN Support Group community of over 9,000 members — is not about LDN itself. It is about getting their doctor to consider prescribing it.

The frustration is understandable. You have done your research. You have read about other patients whose chronic pain, autoimmune symptoms, or fatigue improved. You may have found peer-reviewed studies suggesting benefit for your specific condition. And yet, when you raise it with your physician, the response is often dismissive, noncommittal, or simply "I've never heard of that."

This is not necessarily your doctor's fault, and it does not mean LDN is without merit. What it usually reflects is a systemic gap: the published evidence for LDN has grown considerably over the past decade, but it has not yet penetrated most standard medical training. Understanding why that gap exists — and knowing how to bridge it respectfully — is the purpose of this guide.

At its core, this is a conversation about shared decision-making: the collaborative process in which patients and physicians bring different knowledge to the same table. You bring your experience of your illness. Your physician brings clinical training and the responsibility to evaluate evidence. Neither party has the full picture alone. The strategies in this article are designed to make that collaboration work [18,19].

Why Many Physicians Hesitate to Prescribe LDN

Before preparing your approach, it helps to understand the legitimate reasons a physician might be reluctant. These are real clinical and professional considerations — not excuses — and acknowledging them during your conversation signals that you are an informed patient, not someone pushing a fringe remedy.

Unfamiliarity

The most common barrier is simply not knowing enough about LDN. Naltrexone is taught in medical school as a 50 mg medication for opioid and alcohol use disorders. The idea that one-tenth of that dose might exert entirely different pharmacological effects — through TLR4 antagonism on microglial cells rather than classical opioid receptor blockade — is counterintuitive [1,2]. A 2022 multisite survey found that the most commonly reported barrier to prescribing naltrexone among non-addiction-trained physicians was unfamiliarity with its therapeutic uses [3]. Only about one in four surveyed prescribers had written a naltrexone prescription in the preceding three months — and that survey examined the standard 50 mg dose, not the low-dose applications [3]. The knowledge gap for LDN is far wider.

Off-Label Prescribing Concerns

LDN is not FDA-approved for any of the conditions it is commonly used to treat — fibromyalgia, Crohn's disease, multiple sclerosis, chronic pain, autoimmune conditions, or long COVID. This matters to physicians because prescribing something off-label requires confidence in the supporting evidence. Off-label prescribing is entirely legal and common — studies estimate that 21% to 38% of all outpatient prescriptions in the United States are off-label [4,5]. Gabapentin for neuropathic pain, amitriptyline for migraine prevention, and metformin for polycystic ovarian syndrome are all everyday off-label prescriptions most physicians write without hesitation. But when a physician has not reviewed the evidence for a particular off-label use, hesitation is rational, not obstructionist.

Compounding Pharmacy Requirements

Unlike most medications, LDN cannot be dispensed from a standard pharmacy. Naltrexone is only commercially available as 50 mg tablets (or injectable depot formulations for addiction), so low doses — typically 0.5 to 4.5 mg — must be prepared by a compounding pharmacy. This adds logistical complexity that many physicians have not navigated. Some do not know this pathway exists or how to write a prescription for a compounded medication.

Insufficient Large-Scale Trial Evidence

Physicians are trained to value randomized controlled trials above all other evidence, and the LDN literature has a real limitation: most positive studies are small. The landmark fibromyalgia pilot enrolled 10 participants [6], the crossover trial included 28 [7], and the Crohn's disease pilot involved 17 [8]. The largest and most rigorous fibromyalgia RCT to date — 99 women randomized to naltrexone or placebo for 12 weeks — did not find LDN superior to placebo on its primary pain endpoint, though adverse events were essentially identical between groups [9]. (That trial used a 6 mg dose, which is above the conventional LDN ceiling of 4.5 mg — a detail the LDN clinical community considers relevant, though it does not erase the result.) A physician who looks at this landscape and says "the evidence is promising but limited" is being honest, not dismissive.

Concern About Interactions and Safety Monitoring

The most important safety consideration is well-established: naltrexone at any dose blocks opioid receptors and will reduce or eliminate the effectiveness of opioid pain medications. Perioperative guidelines broadly recommend discontinuing oral naltrexone at least 72 hours before elective surgery, and after discontinuation, opioid responses can become unpredictable due to receptor upregulation [10,11]. Any patient taking LDN must carry this information and disclose it proactively to emergency, surgical, and anesthesia teams. This is a safety issue, not a preference.

Preparing for the Conversation: What to Bring

The difference between a productive conversation and a frustrating one often comes down to preparation. Organized, credible information signals respect for your physician's expertise while giving them the tools they need to evaluate LDN on its merits.

Bring Published Evidence — Not Internet Forums

Physicians respond to peer-reviewed literature. Anecdotes from Facebook groups, however heartfelt, do not carry clinical weight. Fortunately, the LDN evidence base has matured considerably.

The foundational mechanistic review is Younger, Parkitny, and McLain (2014), which established that LDN operates via TLR4 antagonism on microglia — independent of classical opioid receptor effects [1]. Toljan and Vrooman (2018) provide a comprehensive clinical review covering mechanism, dosing, and evidence across multiple conditions [2]. Patten, Schultz, and Berlau (2018) focus specifically on the safety profile, which is consistently favorable [12]. The most recent overview — a 2023 scoping review in Pain Medicine — identified 47 studies across multiple chronic pain conditions [13]. Full citations with PubMed IDs are in the References section; any of these can be printed and handed to your physician.

For condition-specific conversations: the strongest RCT data comes from Crohn's disease, where Smith et al. published an open-label pilot showing 67% remission rates [8] followed by a placebo-controlled trial demonstrating improved mucosal healing [14]. In fibromyalgia, earlier trials showed reduced pain severity and decreased pro-inflammatory cytokines [6,7,15], though as noted above, the largest RCT did not confirm superiority over placebo [9]. In multiple sclerosis, a pilot trial showed improvement in mental-health quality-of-life measures [16]. In long COVID and ME/CFS, a 2026 systematic review in BMJ Open found moderate-to-large favorable effect sizes for fatigue, pain, and sleep — while explicitly noting that no randomized controlled trials were identified and rating overall certainty of evidence as low [17].

Present this evidence honestly. The case for LDN is that it has a plausible mechanism, a favorable safety profile, and a growing but still-developing body of clinical evidence. That is a reasonable basis for a conversation — not a guarantee.

Consider Gifting the LDN Primer

I wrote the Low-Dose Naltrexone (LDN) Primer: 2026 Edition for exactly this situation — a concise, evidence-based introduction that any physician can read in a single sitting. It covers mechanism, conditions where evidence exists, realistic expectations about response rates, dosing, and what LDN cannot do. Chapter 11 includes a sample letter you can bring to your doctor and a practical guide to finding an LDN prescriber.

The Primer is available on Amazon in Kindle and paperback: amazon.com/dp/B0GZ9R4667

Gifting the Primer to your physician shifts the dynamic. Instead of asking them to prescribe something they have never heard of, you are handing them a referenced book from a board-certified colleague and asking them to evaluate it on its merits. The book does the educational work so the conversation can focus on whether LDN is appropriate for you. About two-thirds of patients respond meaningfully to LDN; about one-third do not. The Primer names this openly and devotes a full chapter to what to do when standard LDN does not work. That candor is what builds physician trust.

For clinicians and researchers seeking deeper discussion, the companion volume — LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition) — offers sixteen chapters on pharmacology, evidence, and practical dosing frameworks.

Use Free Educational Resources

Not everyone wants to purchase a book, and not every physician needs one. The full library of referenced articles at www.ifmsynergy.com is available at no cost. Articles particularly useful for physician conversations include:

LDN in Functional Medicine: A Practical Guide — Individualized dosing and clinical integration
15 Teaching Points from the LDN Support Group Pop-Up Live — Evidence-referenced review including the negative fibromyalgia RCT
Integrating LDN Into a Multimodal Strategy for Interstitial Cystitis — 35 peer-reviewed references
LDN, Emotional Distress, Neuropathy, and Mitochondrial Support — Pairing LDN with complementary strategies

These articles include editor's notes where evidence diverges from clinical enthusiasm, negative trial results alongside positive ones, and explicit statements about what remains uncertain. That is the kind of resource a thoughtful physician can trust.

How to Frame the Conversation

Tone matters as much as content. Here are practical approaches drawn from my experience on both sides of the conversation.

Lead With Your Symptoms, Not the Drug

Start with what you are experiencing and what has not worked, not with "I want LDN." A physician is far more receptive to:

"I have been dealing with [condition] for [duration]. I have tried [treatments X, Y, Z] without adequate improvement. In my research, I came across low-dose naltrexone and wanted to ask whether it might be appropriate for me."

The first framing positions you as a partner. Contrast it with: "I read online that LDN can cure [condition] and I want you to prescribe it." The second positions you as someone who has already made the clinical decision and is asking the physician to sign off on it.

Acknowledge What You Do Not Know

Something like: "I understand the evidence is still developing and that LDN is off-label — I am not asking you to promise it will work, I am asking whether it is reasonable to try." This communicates intellectual honesty and makes the physician more willing to engage.

Offer Materials and Time

Hand your physician something they can review at their own pace: "I brought this book [or article] that covers the evidence and dosing. Would you be willing to review it and discuss at our next visit?" This removes the pressure of an on-the-spot decision and respects the reality that a 15-minute appointment is not sufficient to evaluate an unfamiliar therapy.

Bring the Safety Data

One of LDN's strongest arguments is its safety profile. Adverse events across the published literature are consistently mild and typically transient: vivid dreams, mild sleep disturbance, headache, nausea [1,2,12]. In the largest fibromyalgia RCT, adverse event rates were essentially identical between the LDN group (84%) and placebo group (86%) [9]. A physician is more likely to try a therapy with a favorable risk-benefit ratio, even when the efficacy evidence is still developing.

If Your Doctor Says No

A refusal is not necessarily the end of the conversation.

"I'm not comfortable prescribing something I don't know enough about." Respect this — it is honest. Offer the Primer or a review article and ask whether they would be willing to revisit the discussion after reviewing the material. If they say yes, follow up.

"There isn't enough evidence." Partly true and partly a matter of perspective. Acknowledge the limitation while noting that the existing evidence — including the 2023 scoping review covering 47 studies [13] and condition-specific RCTs in Crohn's disease [8,14] — has been substantial enough that Stanford, the University of Alabama at Birmingham, and Dartmouth have all launched clinical trials evaluating LDN. The absence of large Phase III trials reflects the economics of generic medications — no pharmaceutical company will fund a $50 million trial for a drug they cannot patent — not a verdict on efficacy.

"I don't know how to prescribe it." This is a practical barrier, not a philosophical one. LDN must be obtained from a compounding pharmacy. Typical starting doses are 0.5 to 1.5 mg daily, titrated slowly. The Primer covers prescribing details. The LDN Research Trust (ldnresearchtrust.org) also maintains resources for prescribers.

If your physician remains unwilling, consider seeking an integrative or functional medicine physician with LDN experience. The LDN Support Group community is an excellent resource for connecting with knowledgeable prescribers. Calling local compounding pharmacies and asking which physicians in your area prescribe LDN is another practical strategy outlined in Chapter 11 of the Primer.

What Not to Do

Do not present LDN as a miracle cure. It is not. Overclaiming erodes your credibility and your physician's willingness to engage.

Do not self-prescribe. Purchasing naltrexone from unregulated online sources and titrating without medical supervision is unsafe. LDN requires a prescription, a reputable compounding pharmacy, and clinical oversight — particularly for monitoring drug interactions, coordinating perioperative management, and adjusting dosing.

Do not threaten or issue ultimatums. "If you won't prescribe this, I'll find someone who will" — even if true — poisons the relationship and confirms every negative assumption about internet-educated patients.

Do not conflate your experience with evidence. If you have tried LDN through another provider and it helped, share that as your personal experience, not as proof that it works for everyone. Physicians respect the distinction.

A Note About Shared Decision-Making

The modern medical literature recognizes shared decision-making as the standard for clinical care [18,19]. This is mainstream medical ethics, not a radical concept.

What it means practically: you have the right to bring information, ask questions, and participate in decisions about your care. Your physician has the responsibility to evaluate that information against their clinical knowledge and explain their reasoning. Both parties carry obligations. The patient who refuses to hear "no" is not practicing shared decision-making. Neither is the physician who refuses to hear the question.

LDN sits in a space well-suited to shared decision-making: a therapy with a plausible mechanism, a growing evidence base, a favorable safety profile, and enough uncertainty that the patient's values and willingness to try something off-label are legitimately relevant to the clinical decision.

Frequently Asked Questions

Is it legal for my doctor to prescribe LDN off-label? Yes. Off-label prescribing is entirely legal in the United States and accounts for an estimated 21% to 38% of all outpatient prescriptions [4,5]. Any licensed physician can prescribe naltrexone at any dose for any condition they deem clinically appropriate.

Where do I get LDN if my doctor prescribes it? LDN must be obtained from a compounding pharmacy, since naltrexone is only commercially available as 50 mg tablets. Your physician writes a prescription specifying the dose (commonly 0.5–4.5 mg), and the compounding pharmacy prepares it. Many compounding pharmacies ship nationwide.

Can I take LDN with my current medications? LDN is contraindicated with opioid medications — naltrexone blocks opioid receptors and will reduce or eliminate opioid analgesia. Patients on opioids must work with their prescriber to discontinue opioids before starting LDN. Most other medications are compatible, but always disclose your full medication list [10,11].

How long does LDN take to work? Response timelines vary. Some patients notice improvement within weeks; others require two to three months. If there is no meaningful response after an adequate trial at the appropriate dose, LDN may not be the right tool for that individual.

What if my doctor says no? See the detailed section above. In short: respect their reasoning, offer educational materials, and ask whether they would be willing to revisit the conversation. If they remain unwilling, an integrative or functional medicine physician with LDN experience may be a better fit.

Summary Table

Topic	Key Point
Most common physician barrier	Unfamiliarity — LDN is not taught in standard medical training
Off-label status	Legal and routine; 21–38% of all U.S. prescriptions are off-label
Strongest condition-specific evidence	Crohn's disease (RCTs showing remission and mucosal healing)
Broadest evidence survey	47 studies identified across a 2023 scoping review of centralized pain conditions
Honest limitation	Largest fibromyalgia RCT (6 mg dose) did not find superiority over placebo on primary pain outcome
Safety profile	Consistently favorable; adverse events mild and typically transient
Critical safety note	LDN blocks opioid receptors — must disclose to surgical/emergency teams
Must be obtained from	A compounding pharmacy (not available as a commercial low-dose product)
Typical starting dose	0.5–1.5 mg daily, titrated slowly and individualized
Response rate	Approximately two-thirds respond meaningfully; one-third do not
Best resource for physicians	LDN Primer: 2026 Edition (Amazon) or free articles at www.ifmsynergy.com
Best resource for finding a prescriber	LDN Support Group community; local compounding pharmacies

#LDN #LowDoseNaltrexone #LDNPrimer #PatientAdvocacy #SharedDecisionMaking #OffLabelPrescribing #IntegrativeMedicine #FunctionalMedicine #ChronicPain #Fibromyalgia #AutoimmuneDisease #CrohnsDisease #LongCOVID #MECFS #MCAS #Neuroinflammation #DrYoonHangKim #IFMSynergy #LDNSupportGroup #EvidenceBasedMedicine

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2. PMID: 24526250

2. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. doi:10.3390/medsci6040082. PMID: 30248938

3. Lenz JG, Kjellgren RW, Hester BD, et al. Assessing naltrexone prescribing and barriers to initiation for alcohol use disorder: a multidisciplinary, multisite survey. Ment Health Clin. 2022;12(3):174–179. doi:10.9740/mhc.2022.06.174. PMID: 35619618

4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026. doi:10.1001/archinte.166.9.1021. PMID: 16682577

5. Bradford WD, Turner JL, Williams JW. Off-label use of pharmaceuticals: a detection controlled estimation approach. J Ind Econ. 2018;66(4):866–903. doi:10.1111/joie.12189.

6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x. PMID: 19453963

7. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734. PMID: 23359310

8. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/j.1572-0241.2007.01045.x. PMID: 17222320

9. Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31–e39. doi:10.1016/S2665-9913(23)00278-3. PMID: 38258677

10. Agency for Healthcare Research and Quality (AHRQ) PSNet. A painful medication reconciliation mishap — perioperative naltrexone management. psnet.ahrq.gov

11. Whately Y, et al. Perioperative management of patients on naltrexone. Australian and New Zealand College of Anaesthetists resource. ANZCA

12. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086. PMID: 29377216

13. Rupp A, Young E, Chadwick AL. Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270–1281. doi:10.1093/pm/pnad074. PMID: 37302106

14. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56(7):2088–2097. doi:10.1007/s10620-011-1653-7. PMID: 21380937

15. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. doi:10.3390/biomedicines5020016. PMID: 28536359

16. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68(2):145–150. doi:10.1002/ana.22006. PMID: 20695007

17. Byambasuren O, Atkins TJ, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16:e111253. doi:10.1136/bmjopen-2025-111253.

18. Stiggelbout AM, Van der Weijden T, De Wit MPT, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256. doi:10.1136/bmj.e256. PMID: 22286508

19. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi:10.1007/s11606-012-2077-6. PMID: 22618581

All references verified against PubMed or publisher records. Citations reflect the strength and limitations of the underlying evidence, including trials with negative as well as positive results.

https://youtu.be/xON5K7WCRNk?si=jam6BnCTmx4Yosx7

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience spanning preventive medicine, integrative and functional medicine, medical acupuncture, and integrative holistic medicine. A fellowship-trained graduate of the University of Arizona Center for Integrative Medicine under Dr. Andrew Weil, Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness.

He is the author of the LDN Primer: 2026 Edition and LDN for Clinicians, Researchers, and Empowered Patients: Two Decades of Clinical Observation (2026 Edition), and has published more than 20 articles in integrative medicine.

Professional: www.yoonhangkim.com Clinical: www.directintegrativecare.com